isis 113715
Nucleic acidexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2003 (NCT00330330)
Timeline
Indications
Mechanism of action
- Protein-tyrosine phosphatase 1BANTISENSE INHIBITOR
PTPN1 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 113715
- isis 113715
- isis-ptp1b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01918865 | Phase 2 | Aug 1, 2013 | Ionis Pharmaceuticals, Inc. |
| NCT00455598 | Phase 2 | Feb 1, 2007 | Ionis Pharmaceuticals, Inc. |
| NCT00330200 | Phase 2 | Nov 1, 2006 | Ionis Pharmaceuticals, Inc. |
| NCT00365781 | Phase 1 | Aug 1, 2006 | Ionis Pharmaceuticals, Inc. |
| NCT00327626 | Phase 2 | May 1, 2006 | Ionis Pharmaceuticals, Inc. |
| NCT00330330 | Phase 2 | Feb 1, 2003 | Ionis Pharmaceuticals, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 6 | 6 | 2 | 2003 |
1 organizations
Page 1 / 1